Tyche Wealth Partners LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tyche Wealth Partners LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,417 shares of the medical research company’s stock, valued at approximately $1,283,000.

Other institutional investors have also recently made changes to their positions in the company. Coppell Advisory Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $33,000. Live Oak Investment Partners purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $36,000. Tyler Stone Wealth Management purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $37,000. DHJJ Financial Advisors Ltd. purchased a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $38,000. Finally, Raleigh Capital Management Inc. raised its position in Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.6 %

Shares of TMO stock traded down $3.22 on Tuesday, reaching $554.65. 1,010,297 shares of the stock were exchanged, compared to its average volume of 1,539,256. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average price is $571.79 and its 200 day moving average price is $526.53. The company has a market capitalization of $211.72 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 2.38 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter in the prior year, the firm posted $5.40 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. HSBC initiated coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 target price on the stock. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $601.56.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.